Daniel Kantor, MD, Addresses Risk Management in New Multiple Sclerosis Agents

Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with. “Now, until recently that whole idea of risks versus benefits was really about the benefits of the medicine versus the risks of tolerability issues,” said Dr Kantor. “So not of major safety issues.” Self-injectables may be a burden to some, they have a long-term safety profile. Though convenient, newer oral medications have more safety concerns and risks. It is imperative that physicians work with their individual patients to manage risks when using new agents.